MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype

Blood

Volumn 118, Issue 20, 2011, Pages 5550-5558

  Leich, Ellen ^a   Zamo, Alberto ^b   Horn, Heike ^c   Haralambieva, Eugenia ^a   Puppe, Bernhard ^a   Gascoyne, Randy D ^d   Chan, Wing Chung ^e   Braziel, Rita M ^f   Rimsza, Lisa M ^g   Weisenburger, Dennis D ^e   Delabie, Jan ^h   Jaffe, Elaine S ⁱ   Fitzgibbon, Jude ^j   Staudt, Louis M ⁱ   Mueller Hermelink, Hans Konrad ^a   Calaminici, Mariarita ^j   Campo, Elias ^k   Ott, German ^c   Hernández, Luis ^k   Rosenwald, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF VERONA   (Italy)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^k HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; MICRORNA; PROTEIN BCL 2;

ARTICLE; B LYMPHOCYTE; CELL CYCLE REGULATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CONTROLLED STUDY; DOWN REGULATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE TARGETING; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 81555214619     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361972     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
2. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-1992. (Pubitemid 46972781)
3. Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23(26):6394-6399. (Pubitemid 46222239)
4. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114(4):826-834.
5. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer. 2000;27(1):85-94.
6. Gagyi E, Balogh Z, Bodor C, et al. Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. Haematologica. 2008;93(12):1822-1828.
7. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103(2):695-697. (Pubitemid 38140106)
8. Lawrie CH. MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? J Cell Mol Med. 2008;12(5A):1432-1444.
9. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13(7):1248-1260.
10. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732-744.
11. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
12. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2011;42(2):181-185.
13. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol. 2002;198(2):163-170. (Pubitemid 35243874)
14. Hiroki E, Akahira J, Suzuki F, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 2010;101(1):241-249.
15. Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008;112(10):4202-4212.
16. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
17. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11(1):50-54.
18. Zhao JJ, Lin J, Lwin T, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010;115(13):2630-2639.
19. Su H, Yang JR, Xu T, et al. MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69(3):1135-1142.
20. Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell. 2009;137(6):990-992.
21. Shimizu S, Takehara T, Hikita H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010;52(5):698-704.
22. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-1414. (Pubitemid 46970709)
23. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19):4586- 4594.
24. Horsman DE, Okamoto I, Ludkovski O, et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol. 2003;120(3):424-433. (Pubitemid 36241498)
25. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322(5908):1695-1699.
26. Wong CF, Tellam RL. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem. 2008;283(15):9836- 9843.
27. Zhang B, Liu XX, He JR, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011;32(1):2-9.
28. Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of Zeste homolog 2. J Thorac Oncol. 2011;6(4):671-678.
29. Bodor C, O'Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011;25(4):726-729.
30. Meuth M. Chk1 suppressed cell death. Cell Div. 2010;5:21.
31. Phan RT, Saito M, Kitagawa Y, Means AR, Dalla-Favera R. Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat Immunol. 2007;8(10):1132-1139. (Pubitemid 47423761)
32. Starczynski J, Simmons W, Flavell JR, et al. Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. Am J Pathol. 2003;163(2):423-432. (Pubitemid 36909406)
33. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene. 2001;20(40):5638-5643. (Pubitemid 32928103)
34. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81(4):555-564. (Pubitemid 32298801)
35. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
36. Tabrizi SJ, Niiro H, Masui M, et al. T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+memory B cells through altering balances in Bcl-2 family proteins. J Immunol. 2009;182(3):1490-1499.
37. Aggarwal M, Villuendas R, Gomez G, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol. 2009;22(2):206-215.